{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:50:19Z","timestamp":1792108219167,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10928-026-10043-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:16:28Z","timestamp":1784117788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A simple algebraic expression can determine if a drug\u2019s clearance is non-specific or target-mediated"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9870-8418","authenticated-orcid":false,"given":"Liam V","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Penney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys DO","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"10043_CR1","doi-asserted-by":"publisher","unstructured":"Albayrak G, Wan PKT, Fisher K, Seymour LW (2025) T cell engagers: expanding horizons in oncology and beyond. British J Cancer. https:\/\/doi.org\/10.1038\/s41416-025-03125-y","DOI":"10.1038\/s41416-025-03125-y"},{"key":"10043_CR2","doi-asserted-by":"publisher","unstructured":"Wang T, Wang YM, Sun Q (2025) Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA Approvals. Clin Pharmacol Therapeut. https:\/\/doi.org\/10.1002\/cpt.70020","DOI":"10.1002\/cpt.70020"},{"key":"10043_CR3","doi-asserted-by":"publisher","unstructured":"Carretero-Iglesia L, Hall OJ, Berret J, Pais D, Estoppey C, Chimen M, Monney T, Loyau J, Dreyfus C, Macoin J, Perez C, Menon V, Gruber I, Laurendon A, Caro LN, Gudi GS, Matsuura T, Graaf PH, Blein S, Mbow ML, Croasdale-Wood R, Srivastava A, Dyson MR, Matthes T, Kaya Z, Edwards CM, Edwards JR, Maiga S, Pellat-Deceunynck C, Touzeau C, Moreau P, Konto C, Drake A, Zhukovsky EA, Perro M, Pihlgren M (2024) ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nat Cancer 5:1494\u20131514. https:\/\/doi.org\/10.1038\/s43018-024-00821-1","DOI":"10.1038\/s43018-024-00821-1"},{"key":"10043_CR4","doi-asserted-by":"crossref","unstructured":"Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28","DOI":"10.1023\/A:1014414520282"},{"key":"10043_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10928-012-9260-6","volume":"39","author":"LA Peletier","year":"2012","unstructured":"Peletier LA, Gabrielsson J (2012) Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn 39:429\u2013451. https:\/\/doi.org\/10.1007\/s10928-012-9260-6","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10043_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pharmthera.2017.10.011","volume":"184","author":"J Gabrielsson","year":"2018","unstructured":"Gabrielsson J, Peletier LA, Hjorth S (2018) In vivo potency revisited - Keep the target in sight. Pharmacol Therapeut 184:177\u2013188. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.10.011","journal-title":"Pharmacol Therapeut"},{"key":"10043_CR7","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s11095-005-6650-0","volume":"22","author":"DE Mager","year":"2005","unstructured":"Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharmaceut Res 22:1589\u20131596. https:\/\/doi.org\/10.1007\/s11095-005-6650-0","journal-title":"Pharmaceut Res"},{"key":"10043_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573\u2013591. https:\/\/doi.org\/10.1007\/s10928-008-9102-8","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"10043_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1003586","volume":"10","author":"VV Ganusov","year":"2014","unstructured":"Ganusov VV, Auerbach J (2014) Mathematical modeling reveals kinetics of lymphocyte recirculation in the whole organism. PLOS Computat Biol 10(5):1\u201315. https:\/\/doi.org\/10.1371\/journal.pcbi.1003586","journal-title":"PLOS Computat Biol"},{"key":"10043_CR10","doi-asserted-by":"publisher","unstructured":"Brown LV, Gaffney EA, Ager A, Wagg J, Coles MC (2021) Quantifying the limits of car t-cell delivery in mice and men. J Royal Soc Interf 18(176):20201013. https:\/\/doi.org\/10.1098\/rsif.2020.1013. https:\/\/royalsocietypublishing.org\/rsif\/article-pdf\/doi\/10.1098\/rsif.2020.1013","DOI":"10.1098\/rsif.2020.1013"},{"key":"10043_CR11","doi-asserted-by":"publisher","unstructured":"Penney M, Ippolito A, Fevola E, Rata S, Brown L, Gutierrez PM, Jones RD (2025) Predicting the pharmacokinetics of T-Cell Engagers as a function of Target-Mediated Drug Disposition. Clin Transl Sci 18(11). https:\/\/doi.org\/10.1111\/cts.70384","DOI":"10.1111\/cts.70384"},{"issue":"25","key":"10043_CR12","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","volume":"115","author":"SA Beers","year":"2010","unstructured":"Beers SA, French RR, Chan HTC, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PWM, Verbeek JS, Glennie MJ, Cragg MS (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115(25):5191\u20135201. https:\/\/doi.org\/10.1182\/blood-2010-01-263533","journal-title":"Blood"},{"key":"10043_CR13","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.4049\/jimmunol.138.12.4243","volume":"138","author":"F Shirakawa","year":"1987","unstructured":"Shirakawa F, Tanaka Y, Ota T, Suzuki H, Eto S, Yamashita U (1987) Expression of interleukin 1 receptors on human peripheral T cells. J Immunol 138:4243\u20134248","journal-title":"J Immunol"},{"key":"10043_CR14","doi-asserted-by":"publisher","unstructured":"Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: Approximations, identifiability of model parameters and applications to the population pharmacokinetic- pharmacodynamic modeling of biologics. https:\/\/doi.org\/10.1517\/17425250902992901","DOI":"10.1517\/17425250902992901"},{"key":"10043_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/cpt.3302","volume":"116","author":"X Liao","year":"2024","unstructured":"Liao X, Qi T, Zhou J, Liu C, Cao Y (2024) Optimizing Clinical Translation of Bispecific T-cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model. Clin Pharmacol Therapeut 116:415\u2013425. https:\/\/doi.org\/10.1002\/cpt.3302","journal-title":"Clin Pharmacol Therapeut"},{"issue":"16","key":"10043_CR16","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1021\/ja311795d","volume":"135","author":"EF Douglass Jr.","year":"2013","unstructured":"Douglass Jr EF, Miller CJ, Sparer G, Shapiro H, Spiegel DA (2013) A comprehensive mathematical modelfor three-body binding equilibria. J Am Chem Soc 135(16):6092\u20136099. https:\/\/doi.org\/10.1021\/ja311795d","journal-title":"J Am Chem Soc"},{"issue":"Supplement 1","key":"10043_CR17","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/blood-2019-129600","volume":"134","author":"P Horna","year":"2019","unstructured":"Horna P, Nowakowski G, Endell J, Boxhammer R (2019) Comparative assessment of surface cd19 and cd20 expression on b-cell lymphomas from clinical biopsies: Implications for targeted therapies. Blood 134(Supplement 1):5345\u20135345. https:\/\/doi.org\/10.1182\/blood-2019-129600","journal-title":"Blood"},{"key":"10043_CR18","doi-asserted-by":"crossref","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D, Luistro L, Joseph J, Chu G, Packman K, Shetty S, Elsayed Y, Attar R, Gaudet F (2020) A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Immunobiol Immunotherap 135","DOI":"10.1182\/blood.2019003342"},{"key":"10043_CR19","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1182\/blood-2023-177669","volume":"142","author":"I Dekhtiarenko","year":"2023","unstructured":"Dekhtiarenko I, Lelios I, Jacob W, Schneider M, Weisser M, Carlo-Stella C, Manier S, Harrison SJ, Popat R, Riley ACH, Br\u00f6ske A-ME (2023) Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed\/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody. Blood 142:1948\u20131948. https:\/\/doi.org\/10.1182\/blood-2023-177669","journal-title":"Blood"},{"key":"10043_CR20","doi-asserted-by":"crossref","unstructured":"Huijser E, G\u00f6pfert J, Brkic Z, Helden-Meeuwsen CG, Jansen S, Mandl T, Olsson P, Schrijver B, Schreurs MWJ, Daele PLA, Dik WA, Versnel MA (2021) Serum interferon-a2 measured by single-molecule array associates with systemic disease manifestations in Sj\u00f6gren\u2019s syndrome. Rheumatology 61(5):2156\u20132166. https:\/\/doi.org\/10.1093\/rheumatology\/keab688. https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/2156\/43562173\/keab688.pdf","DOI":"10.1093\/rheumatology\/keab688"},{"key":"10043_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/imr.12001","volume":"250","author":"J Piehler","year":"2012","unstructured":"Piehler J, Thomas C, Garcia KC, Schreiber G (2012) Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev 250:317\u2013334. https:\/\/doi.org\/10.1111\/imr.12001","journal-title":"Immunol Rev"},{"key":"10043_CR22","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/jcph.2055","volume":"62","author":"J Almquist","year":"2022","unstructured":"Almquist J, Kuruvilla D, Mai T, Tummala R, White WI, Tang W, Roskos L, Chia YL (2022) Nonlinear population pharmacokinetics of anifrolumab in healthy volunteers and patients with systemic lupus erythematosus. J Clin Pharmacol 62:1106\u20131120. https:\/\/doi.org\/10.1002\/jcph.2055","journal-title":"J Clin Pharmacol"},{"key":"10043_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S (2012) Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1b Monoclonal Antibody. Clin Pharmacokinet 51:1\u201318","journal-title":"Clin Pharmacokinet"},{"key":"10043_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.5114\/aoms.2019.84738","volume":"15","author":"E Robak","year":"2019","unstructured":"Robak E, Gerlicz-Kowalczuk Z, Dziankowska-Bartkowiak B, Wozniacka A, Bogaczewicz J (2019) Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. Arch Med Sci 15:706\u2013712. https:\/\/doi.org\/10.5114\/aoms.2019.84738","journal-title":"Arch Med Sci"},{"issue":"6","key":"10043_CR25","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1002\/jmv.26654","volume":"93","author":"EA Said","year":"2021","unstructured":"Said EA, Al-Reesi I, Al-Shizawi N, Jaju S, Al-Balushi MS, Koh CY, Al-Jabri AA, Jeyaseelan L (2021) Defining IL-6 levels in healthy individuals: A meta-analysis. J Med Virol 93(6):3915\u20133924. https:\/\/doi.org\/10.1002\/jmv.26654","journal-title":"J Med Virol"},{"key":"10043_CR26","doi-asserted-by":"publisher","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu L-T, Tsao A, Sasaki K, Wiest LT, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK (2022) Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy. https:\/\/doi.org\/10.1101\/2022.05.16.492156","DOI":"10.1101\/2022.05.16.492156"},{"issue":"11","key":"10043_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1080\/0284186X.2018.1468084","volume":"57","author":"Y Sun","year":"2018","unstructured":"Sun Y, Reynolds HM, Wraith D, Williams S, Finnegan ME, Mitchell C, Murphy D, Haworth A (2018) Voxel-wise prostate cell density prediction using multiparametric magnetic resonance imaging and machine learning. Acta Oncologica 57(11):1540\u20131546. https:\/\/doi.org\/10.1080\/0284186X.2018.1468084","journal-title":"Acta Oncologica"},{"key":"10043_CR28","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1182\/blood-2023-187349","volume":"142","author":"L Rieger","year":"2023","unstructured":"Rieger L, Irlinger K, Fuechsl F, Barbian N, Tietje M, Faber M, Schulze T, Giansanti P, Besse L, Driessen C, Krackhardt A, Kuster B, Bassermann F (2023) Regulation of BCMA By the Ubiquitin Proteasome System Enables Optimization of BCMA-Targeting Therapies in Multiple Myeloma. Blood 142:3310\u20133310. https:\/\/doi.org\/10.1182\/blood-2023-187349","journal-title":"Blood"},{"key":"10043_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2141.2007.06883.x","volume":"140","author":"GS Ingle","year":"2008","unstructured":"Ingle GS, Chan P, Elliott JM, Chang WS, Koeppen H, Stephan JP, Scales SJ (2008) High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. British J Haematol 140:46\u201358. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06883.x","journal-title":"British J Haematol"},{"key":"10043_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","volume":"112","author":"V Minard-Colin","year":"2008","unstructured":"Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF (2008) Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgRI, FcgRIII, and FcgRIV. Blood 112:1205\u20131213. https:\/\/doi.org\/10.1182\/blood-2008-01-135160","journal-title":"Blood"},{"issue":"6","key":"10043_CR31","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.4049\/jimmunol.1101189","volume":"187","author":"PV Beum","year":"2011","unstructured":"Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PWHI, Winkel JGJ, Taylor RP (2011) Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells. J Immunol 187(6):3438\u20133447. https:\/\/doi.org\/10.4049\/jimmunol.1101189","journal-title":"J Immunol"},{"key":"10043_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1074-7613(00)00066-2","volume":"13","author":"H Liu","year":"2000","unstructured":"Liu H, Rhodes M, Wiest DL, Vignali DAA (2000) On the Dynamics of TCR:CD3 Complex Cell Surface Expression and Downmodulation. Immunity 13:665\u2013675","journal-title":"Immunity"},{"key":"10043_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2967\/jnumed.123.266766","volume":"65","author":"F Lin","year":"2024","unstructured":"Lin F, Clift R, Ehara T, Yanagida H, Horton S, Noncovich A, Guest M, Kim D, Salvador K, Richardson S, Miller T, Han G, Bhat A, Song K, Li G (2024) Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. J Nuclear Med 65:586\u2013592. https:\/\/doi.org\/10.2967\/jnumed.123.266766","journal-title":"J Nuclear Med"},{"key":"10043_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","volume":"70","author":"Y Fu","year":"2019","unstructured":"Fu Y, Urban DJ, Nani RR, Zhang YF, Li N, Fu H, Shah H, Gorka AP, Guha R, Chen L, Hall MD, Schnermann MJ, Ho M (2019) Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology 70:563\u2013576. https:\/\/doi.org\/10.1002\/hep.30326","journal-title":"Hepatology"},{"key":"10043_CR35","doi-asserted-by":"publisher","unstructured":"Filippi L, Frantellizzi V, Urso L, Vincentis GD, Urbano N (2025) Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights. Biomedicines 13. https:\/\/doi.org\/10.3390\/biomedicines13071570","DOI":"10.3390\/biomedicines13071570"},{"key":"10043_CR36","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1681\/ASN.V9122344","volume":"9","author":"L Rostaing","year":"1998","unstructured":"Rostaing L, Chatelut E, Payen J-L, Izopet J, Thalamas C, Tonn H, Pascal J-P, Durand D, Canall P (1998) Pharmacokinetics of aIFN-2b in Chronic Hepatitis C Virus Patients Undergoing Chronic Hemodialysis or with Normal Renal Function: Clinical Implications. J Am Soc Nephrol 9:2344\u20132348","journal-title":"J Am Soc Nephrol"},{"key":"10043_CR37","doi-asserted-by":"crossref","unstructured":"Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M (2001) Prolonging the half-life of human interferon-2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl) 7-interferon-2. PNAS","DOI":"10.1073\/pnas.98.3.1212"},{"key":"10043_CR38","doi-asserted-by":"publisher","unstructured":"Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, Vainshtein I, Farmer E, Rosenthal K, Morehouse C, Reyes MDL, Schifferli K, Liang M, Sanjuan MA, Sims GP, Kolbeck R (2018) Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med 5. https:\/\/doi.org\/10.1136\/lupus-2018-000261","DOI":"10.1136\/lupus-2018-000261"},{"key":"10043_CR39","doi-asserted-by":"publisher","unstructured":"Chmiest D, Sharma N, Zanin N, Lesegno CVD, Shafaq-Zadah M, Sibut V, Dingli F, Hup\u00e9 P, Wilmes S, Piehler J, Loew D, Johannes L, Schreiber G, Lamaze C (2016) Spatiotemporal control of interferon-induced JAK\/STAT signalling and gene transcription by the retromer complex. Nat Commun 7. https:\/\/doi.org\/10.1038\/ncomms13476","DOI":"10.1038\/ncomms13476"},{"key":"10043_CR40","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood.V77.8.1627.1627","volume":"77","author":"CA Dinarello","year":"1991","unstructured":"Dinarello CA (1991) Interleukin-1 and Interleukin-1 Antagonism. Blood 77:1627\u20131652","journal-title":"Blood"},{"key":"10043_CR41","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/eji.1830190821","volume":"19","author":"J Klapproth","year":"1989","unstructured":"Klapproth J, Castell J, Geiger T, Andus T, Heinrich PC (1989) Fate and biological action of human recombinant interleukin 1b in the rat in vivo. European J Immunol 19:1485\u20131490. https:\/\/doi.org\/10.1002\/eji.1830190821","journal-title":"European J Immunol"},{"key":"10043_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1084\/jem.20082481","volume":"206","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung T (2009) In vivo regulation of interleukin 1b in patients with cryopyrin-associated periodic syndromes. J Experiment Med 206:1029\u20131036. https:\/\/doi.org\/10.1084\/jem.20082481","journal-title":"J Experiment Med"},{"key":"10043_CR43","doi-asserted-by":"publisher","unstructured":"S Z, F S, B J, D F, B G, I N, Z Z, J H, R M, T O, W, W (2020) Characterization of concurrent target suppression by jnj-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17a. MAbs 12(1), 1770018. https:\/\/doi.org\/10.1080\/19420862.2020.1770018","DOI":"10.1080\/19420862.2020.1770018"},{"key":"10043_CR44","doi-asserted-by":"publisher","unstructured":"WP C, MJ M, K R, SJ B, S W, Y Z, W W, Z C, PB S, Y J, CC C, J C, R H, RR C (2020) The cytokine il-17a limits th17 pathogenicity via a negative feedback loop driven by autocrine induction of il-24. Immunity 53(2):384\u20133975. https:\/\/doi.org\/10.1016\/j.immuni.2020.06.022","DOI":"10.1016\/j.immuni.2020.06.022"},{"key":"10043_CR45","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.4049\/jimmunol.138.9.2906","volume":"138","author":"M Sb","year":"1987","unstructured":"Sb M, Pl K, Jc L, Ka P, Ra C (1987) Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J Immunol 138:2906\u20132912","journal-title":"J Immunol"},{"key":"10043_CR46","doi-asserted-by":"publisher","unstructured":"Silva RCMC, Travassos LH, Dutra FF (2024) The dichotomic role of single cytokines: Fine-tuning immune responses. Cytokine 173. https:\/\/doi.org\/10.1016\/j.cyto.2023.156408","DOI":"10.1016\/j.cyto.2023.156408"},{"key":"10043_CR47","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/cpt.2129","volume":"109","author":"ME Lassman","year":"2021","unstructured":"Lassman ME, Chappell DL, McAvoy T, Cheng A, Alwis DP, Pruitt SK, Laterza OF, Li C, Stoch A, Mayawala K (2021) Experimental Medicine Study to Measure Immune Checkpoint Receptors PD-1 and GITR Turnover Rates In Vivo in Humans. Clin Pharmacol Therapeut 109:1575\u20131582. https:\/\/doi.org\/10.1002\/cpt.2129","journal-title":"Clin Pharmacol Therapeut"},{"key":"10043_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/cpt.2170","volume":"110","author":"TR Li","year":"2021","unstructured":"Li TR, Chatterjee M, Lala M, Abraham AK, Freshwater T, Jain L, Sinha V, Alwis DP, Mayawala K (2021) Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology. Clin Pharmacol Therapeut 110:200\u2013209. https:\/\/doi.org\/10.1002\/cpt.2170","journal-title":"Clin Pharmacol Therapeut"},{"key":"10043_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.18632\/genesandcancer.13","volume":"5","author":"IM Gomes","year":"2014","unstructured":"Gomes IM, Santos CR, Maia CJ (2014) Expression of STEAP1 and STEAP1B in prostate cell lines, and the putative regulation of STEAP1 by post-transcriptional and post-translational mechanisms. Genes & Cancer 5:3\u20134","journal-title":"Genes & Cancer"},{"key":"10043_CR50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","volume":"14","author":"O Nolan-Stevaux","year":"2024","unstructured":"...Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, Staley BK, Stevens J, Cooke KS, Aeffner F, Thomas O, Stieglmaier J, Lee JL, Coxon A, Bailis JM (2024) AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov 14:90\u2013103. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0984","journal-title":"Cancer Discov"},{"key":"10043_CR51","unstructured":"FDA (2020) Anifrolumab FDA Pharmacology Review 761123Orig1s000. Technical report, Federal Drug Agency"},{"key":"10043_CR52","doi-asserted-by":"publisher","unstructured":"Kulikov A, Shipaeva E, Dmitrieva A, Batrak V, Shipunov G, Guy C, Smith J, Zhang R, Zhang M, Duan J, Chestukhin A, Barbashov S, Samsonov M, Lavrovsky Y (2021) Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.723038","DOI":"10.3389\/fphar.2021.723038"},{"key":"10043_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/bcpt.13202","volume":"125","author":"S Timmermann","year":"2019","unstructured":"Timmermann S, Hall A (2019) Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. Basic Clin Pharmacol Toxicol 125:16\u201325. https:\/\/doi.org\/10.1111\/bcpt.13202","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10043_CR54","doi-asserted-by":"publisher","unstructured":"Waaijer SJH, Giesen D, Ishiguro T, Sano Y, Sugaya N, Schr\u00f6der CP, Vries EGED, Hooge MNL-D (2020) Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. J ImmunoTherap Cancer 8. https:\/\/doi.org\/10.1136\/jitc-2020-000548","DOI":"10.1136\/jitc-2020-000548"},{"key":"10043_CR55","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.xphs.2021.12.019","volume":"111","author":"N Frances","year":"2022","unstructured":"Frances N, Bacac M, Bray-French K, Christen F, Hinton H, Husar E, Quackenbush E, Sch\u00e4fer M, Schick E, Vyver AVD, Richter WF (2022) Novel in Vivo and in Vitro Pharmacokinetic\/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. J Pharmaceut Sci 111:1208\u20131218. https:\/\/doi.org\/10.1016\/j.xphs.2021.12.019","journal-title":"J Pharmaceut Sci"},{"key":"10043_CR56","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","volume":"83","author":"M Shirley","year":"2023","unstructured":"Shirley M (2023) Glofitamab: First Approval. Drugs 83:935\u2013941. https:\/\/doi.org\/10.1007\/s40265-023-01894-5","journal-title":"Drugs"},{"key":"10043_CR57","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2018-99-113921","volume":"132","author":"C-L Law","year":"2018","unstructured":"Law C-L, Aaron W, Austin R, Barath M, Callihan E, Evans T, Guerrero MG, Hemmati G, Jones A, Kwant K, Lao L, Lemon B, Moldt K, Patnaik P, Sexton K, Wesche H, Xiao Y, Yu S, Yu T (2018) Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma. Blood 132:3225\u20133225. https:\/\/doi.org\/10.1182\/blood-2018-99-113921","journal-title":"Blood"},{"key":"10043_CR58","doi-asserted-by":"publisher","first-page":"14979","DOI":"10.1074\/jbc.M115.652156","volume":"290","author":"V Oganesyan","year":"2015","unstructured":"Oganesyan V, Peng L, Woods RM, Wu H, Dall\u2019Acqua WF (2015) Structural insights into the neutralization properties of the fully human, anti-interferon monoclonal antibody sifalimumab. J Biol Chem 290:14979\u201314985. https:\/\/doi.org\/10.1074\/jbc.M115.652156","journal-title":"J Biol Chem"},{"key":"10043_CR59","unstructured":"Sirukumab NovoPro Datasheet (2025). https:\/\/www.novoprolabs.com\/p\/sirukumab-anti-il-6-ifnb2-antibody-176816.html. Accessed 16 Sep 2025"},{"key":"10043_CR60","unstructured":"Human Use (CHMP) Assessment\u00a0report EMAC (2022) Tecvayli European Medicines Agency Report. Technical report, European Medicines Agency"},{"key":"10043_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/OARRR.S17118","volume":"3","author":"M Mihara","year":"2011","unstructured":"Mihara M, Ohsugi Y, Kishimoto T (2011) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatol: Res Rev 3:19\u201329. https:\/\/doi.org\/10.2147\/OARRR.S17118","journal-title":"Open Access Rheumatol: Res Rev"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10043-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10043-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10043-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:21:36Z","timestamp":1792106496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10043-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10043"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10043-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8519494\/v1","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LVB, MP and RDOJ are employees and shareholders in AstraZeneca. AI was formerly an employee and shareholder in AstraZeneca. AI is an employee and shareholder in Merck KGaA.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Declaration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"39"}}